37 results about "Thromboplastin" patented technology

The invention is a fibrin glue that avoids the use of fibrinogen and thus eliminates the need for premixing and premature clot formation. The fibrin glue of the invention comprises thrombin, thromboplastin and calcium and may have clotting Factors, VII, IX and X, and the like. The invention also comprises a biosealant for use with the fibrin glue without fibrinogen or for use alone. The biosealant is a two component mixture of gelatin/resorcinol and glyoxal/glutaraldehyde/4-(p-maleimidophenyl) butyric acid. The two components are mixed on use.

Disclosed herein are wound dressings comprising fibrinogen and at least one procoagulant such as propyl gallate in a therapeutic amount. Also disclosed are methods of treating wounds, increasing an amount of or rate of coagulation of blood from a wound, increasing an amount of or rate of clot formation over a wound, increasing blood platelet counts, activating a coagulation system, increasing the plasma concentration of fibrinogen, and decreasing the activated partial thromboplastin time. Also disclosed are an arterial bleeding model and methods of studying arterial bleeding.

The invention discloses a cordyceps militaris health-care beverage prepared by liquid submerged fermentation and a preparation method thereof. The preparation method comprises the following steps: sequentially performing culture activation, shake culture, seeding tank cultivation and fermentation tank cultivation on cordyceps militaris, then achieving high-temperature extraction of effective components and thromboplastin killing to obtain fermentation liquor, and finally conducting filtering, blending, sterilizing, subpackaging and other procedures to obtain the health-care beverage product. The cordyceps militaris health-care beverage is prepared by adopting the liquid submerged fermentation technology, is simple in process and free from influences of seasons and weather, meets the large-scale periodic production requirement, is short in producting cycle, low in cost, and excellent and stable in product quality, and has unique heavy fragrance, efficiency and properties of cordyceps militaris, thereby obtaining very wide market prospect.

The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having improved FIX clotting activity. Three full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assays in FIX-depleted plasma. Two mutant proteins had increased specific FIX activity. Furthermore, a pre-activated FIX protein had an increased activity in FIX-depleted plasma. Therefore these FIX mutants can be used for the treatment of FIX associated bleeding disorders.

The invention relates to a method for preparing a liquid porcellanite activating partial thromboplastin (APTT) reagent. The reagent is mainly used for monitoring coagulation factor deficiency of endogenous coagulation systems and carrying out screening test of related inhibitors, and used for detecting coagulation factors, heparin anticoagulation treatment and lupus anticoagulation substances as the current main means. Taking porcellanite as an activating agent, the method improves the sensitivity to the coagulation factors; a novel stable system solves the problem of keeping the stability of the reagent at a liquid state; and the method has the advantages of high sensitivity, convenient use, small experimental error, strong stability, good compatibility, low cost and the like.

An activated partial thromboplastin time measuring reagent, comprising a heparin neutralizer is disclosed. An activated partial thromboplastin time measuring method, and a determination method for determining a presence or absence of a blood coagulation inhibitor are also disclosed.

The present invention provides a method for measuring activated partial thromboplastin time. The method comprises: a first mixing step of mixing a blood plasma with a first reagent, wherein the first reagent comprises an activator and phosphatidylglycerol at a concentration equal to or greater than 25 μg/mL; a second mixing step of mixing a sample obtained in the first mixing step with a second reagent comprising a calcium salt; and a step of measuring coagulation time of the sample obtained in the second mixing step.

A thromboplastin reagent includes tissue factor, Factor VIIa, and a net negatively charged phospholipid. The thromboplastin reagent is a synthetic thromboplastin reagent, and is in dried form.

A kit for measuring activated partial thromboplastin time (APTT) is provided. The kit includes R1 including an activator, partial thromboplastin, a stabilizer, an aseptic and a buffer liquid; and R2 that is a calcium chloride solution. The stabilizer includes dextran. In the R1, the concentration of the activator is 0.05-0.2 mM, the content of the partial thromboplastin is 0.1-0.5 wt%, the contentof the aseptic is 0.01-0.02 wt% and the content of the dextran is 2-4 wt%. All agents in the kit are liquid and stable so that reagent differences among bottles caused by freeze-drying and redissolving processes in preparation and application processes, thus avoiding large differences among measurement results. Stability of the reagents can be ensured without the need of freeze drying, and optimum validity of the reagents after bottle opening is at least a month, thus avoiding large differences among experiment results, reducing using amounts of the reagents, achieving instant use after bottle opening, and making operation rapider and simpler.

The invention belongs to the field of biotechnology and aims to solve clinic standardization problem for PT determination. The quality of a PT reagent is a key factor influencing PT test, and the effective method for reducing the difference of determination results in different laboratories is to unify the chemical composition and biochemical characterics of thromboplastin in reagent. The recombined thromboplastin prepared by genetic engineering method has stable molecular structure and uniform protein, and can improve test sensitivity, precision and accuracy. The full-length human thromboplastin expressed by yeast cell can achieve high purity and target protein with high activity by one-step purification. The invention also provides a method for preparing liquid PT reagent based on recombined thromboplastin. The reagent has good sensitivity and stability and qualified each technical index, and test shows that the reagent is suitable for clinic application.

The invention provides a thromboplastin reagent comprising: tissue factor, a phospholipid and a polyphosphate that acts as a blocker of tissue factor pathway inhibitor (TFPI). Also provided are a composition for promoting clotting comprising polyphosphate, and a reagent for a clotting assay also comprising polyphosphate together with an activator of clotting. Methods for stopping or slowing wound bleeding and fibrinolysis using compositions comprising polyphosphate are also disclosed.

There is proposed a chemical compound of 5,11,17,23-tetrakis[bis(dihydroxyphosphoryl)methyl]calix[4]arene and a sodium salt thereof, which can be used as antithrombotic agents. A highly specific inhibiting effect of the aforementioned calixarenes on the fibrin polymerization has been identified. It has been found that the addition of the aforementioned calixarenes to blood plasma leads to an increase of the prothrombin time and the activated partial thromboplastin time.

The invention provides a preparation method of a lyophilization type determination PT reagent. Raw materials comprise HEPES buffer solution, synthetic phospholipids, a recombinant sheep tissue factor,a lyoprotectant and a preservative. The preparation method comprises the following steps: adding the lyoprotectant into prepared HEPES buffer solution, dissolving an appropriate amount of synthetic phospholipids in HEPES buffer solution containing 1% triton X-100, dissolving a sheep tissue factor in an appropriate amount of PBS buffer solution to form 55[mu]g/ml tissue factor solution, adding therecombinant sheep tissue factor into phospholipid solution, finally adding the preservative and lyoprotectant solution into phospholipid tissue factor solution, and performing lyophilization on the obtained supernate by virtue of the conventional technology, thus the PT reagent product is obtained. The preparation method provided by the invention optimizes a formula of a prepared thromboplastin lyoprotectant on the basis of existing components, the problem of loss of thromboplastin in an existing prothrombin detection reagent lyophilizing process is solved, sensitivity is relatively high, a validity period of the reagent is prolonged, and production is easy. The reagent has high clinical application value and potential market benefit.

The invention relates to a method for synthesizing (R)-2-(t-butyloxycarboryl)-4-(2-pyridyl) butyric acid and aims to solve technical problems that a conventional synthesis method is expensive in raw material, harsh in reaction condition and the like. The method has the synthesis route as shown in the specification. As non-natural protected amino acid which is high in price, (R)-2-(t-butyloxycarboryl)-4-(2-pyridyl) butyric acid is not only applied to the field of polypeptide biological pharmacy, but also is an important intermediate for synthesizing a novel thromboplastin FXa blocker and 2-aminomethyl-5-chlorobenzylamine derivative.

Disclosed is a reagent for determination of activated partial thromboplastin time, comprising: a phosphatidylcholine (PC); a phosphatidylserine (PS); and a phosphatidylethanolamine (PE), wherein a concentration ratio of the PS relative to the PC is not less than 0.16 and not more than 0.25, and a concentration of the PS is not less than 7 μg/mL and not more than 13 μg/mL.

In order to determine the intraoperative risk of bleeding preoperatively, both the content of fibrin monomer (FM) and the partial thromboplastin time (PTT) are determined in a blood or plasma sample.